13.09.2011 • News

Novartis Expects Annual Cost Synergies of $350 Million From Alcon Integration

Novartis Tuesday said it now expects the integration of Alcon as an eye care segment to create annual cost synergies of $350 million by 2013. In January 2010, on acquiring a 77% majority stake in Alcon from Nestle, Novartis had estimated generating annual pre-tax cost synergies of approximately $200 million "within three years".

Updating on Alcon's performance, the company noted that both sales and core operating income had registered double-digit growth in the last 18 months.

Novartis's Chief Executive Officer Joseph Jimenez commented "This transaction was about long-term growth and not just cost synergies. We believe that Alcon has significant growth potential by leveraging the Novartis expertise in research, market access, and reimbursement, among others."

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read